High-Content Fluorescent-Based Assay for Screening Activators of DNA Damage Checkpoint Pathways

Abstract

Activation of DNA damage checkpoint pathways, including Chk2, serves as an anticancer barrier in precancerous lesions. In an effort to identify small-molecule activators of Chk2, the authors developed a quantitative cell-based assay using a high-content analysis (HCA) platform. Induction of phosphorylated Chk2 was evaluated using several different parameters, including fold induction, Kolmogorov-Smirnov score, and percentage of positively stained cells. These measurements were highly correlated and provided an accurate method for compound ranking/binning, structure-activity relationship studies, and lead identification. Screening for Chk2 activators was undertaken with a target-focused library and a diversified library from ArQule chemical space. Several compounds exhibited submicromolar EC₅₀ values for phosphorylated Chk2 induction. These compounds were further analyzed for Chk2-dependent cytotoxicity, as assessed through a high-content cell death assay in combination with siRNA silencing of Chk2 expression. Several compounds were identified and showed specific inhibition or lethality in a target-dependent manner. Therefore, identification of DNA damage checkpoint pathway activators by HCA is an attractive approach for discovering the next generation of targeted cancer therapeutics. (Journal of Biomolecular Screening 2008:538-543)

Keywords

high-content analysis Chk2 fold induction KS score percentage of positively stained cells

References

Collins I. , Workman P : New approach to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700.

Workman P : Genomics and the second golden era of cancer drug development. Mol Biosyst 2005;1:17-26.

Workman P. : Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics. Cold Spring Harb Symp Quant Biol 2005;70:499-515.

Sancar A. , Lindsey-Boltz LA , Unsal-Kacmaz K. , Linn S. : Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints . Annu Rex Biochem 2004;73:39-85.

Bartkova J. , Horejsi Z. , Koed K. , Kramer A. , Totf F. , Zieger K. , et al: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.

Gorgoulis VG , Vassiliou LV , Karakaidos P. , Zacharatos P. , Kotsinas A. , Liloglou T. , et al: Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:829-830.

Kastan MB , Bartek J. : Cell-cycle checkpoints and cancer. Nature 2004; 432:316-323.

Bartek J. , Lukas J. : Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-429.

Chen CR , Wang W. , Rogoff HA , Li X. , Mang W. , Li CJ : Dual induction of apoptosis and senescence in cancer cells by Chk2 activation: checkpoint activation as a strategy against cancer. Cancer Res 2005;65:6017-6021.

10.

Li CJ : Therapeutic biology: checkpoint pathway activation therapy, HIV Tat, and transkingdom RNA interference. J Cell Physiol 2006;209:695-700.

11.

Rausch O : High-content cellular screening. Curr Opin Chem Biol 2006; 10:316-320.

12.

Lee S. , Howell BJ : High-content screening: emerging hardware and software technologies . Methods Enzymol 2006;414:468-483.

13.

Haney SA , LaPan P. , Pan J. , Zhang J. : High-content screening moves to the front of the line. Drug Discov Today 2006;11:889-894.

14.

Evans DM , Azorsa DO , Mousses S. : Genome scale cytometry: high-content analysis for high throughput RNAi phenotype profiling. Drug Discov Today Technol 2005;2:141-146.

15.

Bell DW , Varley JM , Szydlo TE , Kang DH , Wahrer DC , Shannon KE , et al: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome . Science 1999;286:2528-2531.